CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company…Read More
Exicure Inc Reports First Quarter 2023 Financial Results and Provides Corporate Update
